Insmed Incorporated (INSM)
| Previous Close | 57.00 |
| Open | 57.40 |
| Bid | 57.49 x 300 |
| Ask | 71.74 x 200 |
| Day's Range | 55.81 - 58.27 |
| 52 Week Range | 18.77 - 58.82 |
| Volume | |
| Avg. Volume | 2,897,393 |
| Market Cap | 9.414B |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.23 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 64.47 |
PR NewswireInsmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Monday, June 10, 2024, at 10:00 a.m. ET.
- PR Newswire
Insmed to Host Commercial Webinar on June 4, 2024
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host a commercial webinar on Tuesday, June 4, 2024, at 8:00 a.m. ET to discuss the market outlook for the Company's three most advanced programs, ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP).
- PR Newswire
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it priced an underwritten public offering of 12,621,359 shares of its common stock at a price to the public of $51.50 per share. The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, are expected to be approximately $650 million. I
